

PCT/IL2004/000642

15 JUL 2004

REC'D 03 AUG 2004

WIPO

PCT

PA 1165546

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

May 06, 2004


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/487,956

FILING DATE: July 18, 2003

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



M. K. HAWKINS

Certifying Officer

PATENT APPLICATION SERIAL NO. _____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

07/21/2003 KBETEM1 00000077 501407 60457936
01 FC:2003 80.00 DA

PTO-1556
(5/87)

07/18/03
3698 U.S.
4713 U.S. PTO
60/48756

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (b)(2)

Docket Number		26421		Type a plus sign (+) inside this box ->	
INVENTOR(s) / APPLICANT(s)					
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)		
MOR	Amram		Haifa, Israel		
TITLE OF THE INVENTION (280 characters max)					
A DERMASEPTIN DERIVATIVE (DD ₁₃) PREVENTS GRAFT ASSOCIATED INFECTIONS OF ANTIBIOTIC-RESISTANT STAPHYLOCOCCI					
CORRESPONDENCE ADDRESS					
G. E. EHRLICH (1995) LTD. c/o ANTHONY CASTORINA 2001 JEFFERSON DAVIS HIGHWAY SUITE 207					
STATE	VIRGINIA	ZIP CODE	22202	COUNTRY	USA
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification	Number of Pages	23	<input checked="" type="checkbox"/> Applicant is entitled to Small Entity Status		
<input checked="" type="checkbox"/> Drawing(s)	Number of Sheets	4	<input checked="" type="checkbox"/> Other (specify)		
			3 Claims		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees			FILING FEE AMOUNT (\$)		\$ 80.-
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number:			50-1407		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.



No



Yes, the name of the US Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE

Sol Sheinbein

16 July 2003

25,457

REGISTRATION NO.
(if appropriate)

TYPED or PRINTED NAME SOL SHEINBEIN



Additional inventors are being named on separately numbered sheets attached hereto

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

Burden House Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, DC 20231.

INTRODUCTION

Documentation of nosocomial infections due to *Staphylococcus aureus* and *Staphylococcus epidermidis* is increasing over the last decades (39, 34). These common skin inhabitant bacteria are known to be a frequent cause of infections related to prosthetic and indwelling medical devices (14, 43). Several infections are related to bacterial biofilm formation on material surfaces, such as those of venous or urinary catheters, prosthetic heart valves, orthopaedic devices, and even contact lenses (14, 43, 61, 38). In particular, the late-appearing vascular graft infections are one of the most feared complications that the vascular surgeon treats, frequently resulting in prolonged hospitalization, organ failure, amputation, and death (7, 32). Effective strategies for the prevention of prosthetic infection vary from device to device, even though, the capacity of staphylococci to produce a biofilm often makes them resistant to conventional antimicrobial agents (66, 41). The centerpiece of therapy is prophylactic systemic antibiotics. However, recent prophylactic strategies suggested the use of antimicrobials bound in high concentrations to prosthetic grafts have been proposed as added prophylaxis (60, 11, 68). Several studies have focused on developing new prosthetic materials that reduce adhesion or survival of bacteria (68, 26). One of the most interesting studies was based on the fact that resistance of biofilm to antimicrobial agents is acquired as a multi-cellular strategy that relies on exchange of chemical signals between cells in a process known as quorum sensing (45). Thus, interfering with this mechanism of bacterial cell-cell communication could provide a novel approach to prevent biofilm formation. Recently, a seven amino acid peptide termed RNAIII inhibiting peptide (RIP) was described to affect diseases caused by *S. aureus* and *S. epidermidis* (5, 2, 27, 70, 3, 24, 6).

RIP was shown to inhibit *S. aureus* and *S. epidermidis* pathogenesis (biofilm formation (6) and toxin production (70)) by disrupting quorum sensing mechanisms through inhibition of TRAP phosphorylation (4). TRAP is a protein unique to staphylococci but is

highly conserved among strains and species, and therefore its inhibitor RIP was effective against any staphylococcal strain so far tested (2, 27, 70, 3, 24). RIP does not directly kill the bacteria but interferes with its signal transduction, thus making it non pathogenic.

The ubiquitously produced in nature cationic antimicrobial peptides (9, 54, 28, 29, 21, 1, 37, 69) are attracting increasing research and clinical interest for their roles in innate immunity and for their potential uses in various antimicrobial fields (47, 71). The cytoplasmic membrane was proposed to be their ultimate target. Being cationic, the peptides are able to interact electrostatically with the negatively charged phospholipid headgroups and then insert into the membrane bilayer in a manner that leads to its disruption (40, 31, 33, 62). Although the steps involved in this mechanism remain to be delineated, there is a large body of experimental data demonstrating antimicrobial peptides to display a direct correlation between antibiotic effect and increased plasma membrane permeability, conductance of ions across lipid bilayers and dissipation the trans-membrane electric potential (59, 37, 46, 55, 20, 65, 56, 63, 37, 22, 16). Thus, while their precise mechanism of action is not fully understood, their microbicidal effect is believed to result from the peptides capacity to disrupt the ordered membrane structure of target cells. The molecular basis for selective activity between mammalian and bacterial cells is also ill defined, but is believed to result from differences in the lipid composition of target versus non-target cells, such as membrane fluidity and high negative charge density (1, 71, 42, 12). These differences seem to be responsible for the preferred accumulation of antimicrobial peptides on microbial membranes. Numerous studies have demonstrated that the peptides physicochemical properties, i.e., amphipathy, positive charge content and hydrophobicity are the main factors affecting membrane-lysis activity (1, 42, 12, 8). Accordingly, isomers composed of all D-amino acids are as active as the L-enantiomers, implying that the mechanism of action is not mediated by interaction with a

stereo-specific receptor. These properties enable cationic antimicrobial peptides to escape microbial mechanisms involved in multidrug resistance (12, 23, 53).

Dermaseptins are a large family of linear polycationic peptides from frog skin (50, 51, 48, 10) whose cytolytic activity is believed to result from interaction of their N-terminal domain with the plasma membranes of target cells (49, 52). Recent investigations with respect to the relations between physical properties (structure and organization in solution) of dermaseptin S4 and its interaction with target membranes (18, 35) led to the design of short derivatives that maintain the amphipathic alpha-helical structure of the parent peptide, bind avidly to model membranes with association affinity constants (K_A) in the range of 10^5 to 10^7 M^{-1} and exert rapid cytolytic activity against a variety of pathogens. Among these, the 13-mer derivative K_4 -S4(1-13)_a is of particular interest as it is the smallest derivative that combines low toxicity and efficient large-spectrum antimicrobial activity both in culture and in animal models of infection (53, 19).

In this disclosure, I show that RIP and the 13-mer dermaseptin derivative DD₁₃ individually inhibit biofilm formation on a Dacron graft and that the bactericidal peptide efficiently eradicates drug resistant staphylococcal infections.

MATERIALS and METHODS

Peptides: Peptides were synthesized by the solid phase method as described (35), applying the Fmoc active ester chemistry on a fully automated, programmable "Model 433A Peptide Synthesizer" (Applied Biosystems). MBHA-resin (Novabiochem, Germany) was used to obtain amidated peptides. The crude peptides were extracted from the resin with 30% acetonitrile in water and purified to chromatographic homogeneity in the range of 98 to >99% by reverse-phase HPLC (Alliance-Waters). HPLC runs were performed on a semipreparative C4 column (Vydac) using a linear gradient of acetonitrile in water (1%/min), both solvents

containing 0.1% trifluoroacetic acid. The purified peptides were subjected to amino acid analysis and electrospray mass spectrometry in order to confirm their composition. Peptides were stored as a lyophilized powder at -20°C.

Bacteria: Methicillin-resistant *S. aureus* (MRSE) ATCC 43300 was commercially purchased from Oxoid S.p.A., Milan, Italy. Methicillin-resistant *S. epidermidis* (MRSE) is a clinical strain from the Institute of Infectious Diseases and Public Health, University of Ancona, Italy.

Animals: Adult male Wistar rats, 250-300gr (I.N.R.C.A. I.R.R.C.S. animal facility, Ancona) were used, with 15 animals per experimental group.

Susceptibility testing: The antimicrobial susceptibilities of the strains were determined by using the microbroth dilution method, according to the procedures outlined by the National Committee for Clinical Laboratory Standards. The minimal inhibitory concentration (MIC) was taken as the lowest antibiotic concentration at which observable growth was inhibited. Experiments were performed in triplicate.

Graft infection rat model: Rats were anesthetized and their hair of the back was shaved and the skin cleansed with 10% povidone-iodine solution. One subcutaneous pocket was made on each side of the median line by a 1.5 cm incision. Aseptically, 1-cm² sterile albumin-sealed Dacron grafts (Albograft™, Sorin Biomedica Cardio, S.p.A., Saluggia VC, Italy) were implanted into the pockets. Before implantation grafts were soaked for 20 minutes in sterile solutions of the various agents. The pockets were closed by means of skin clips and saline solution (1 mL) containing MRSA or MRSE at a concentration of 2×10^7 cfu/mL was inoculated onto the graft surface by using a tuberculin syringe to create a subcutaneous fluid-filled pocket. The animals were returned to individual cages and thoroughly examined daily. All grafts were explanted at 7 days following implantation.

Assessment of the infection: The explanted grafts were placed in sterile tubes, washed in sterile saline solution, placed in tubes containing 10 mL of phosphate-buffered saline solution and sonicated for 5 minutes to remove the adherent bacteria from the grafts (6). Quantitation of viable bacteria was performed by culturing serial dilutions (0.1 mL) of the bacterial suspension on blood agar plates. All plates were incubated at 37°C for 48 hours and evaluated for the presence of the staphylococcal strains. The organisms were quantitated by counting the number of colony-forming units (CFUs) per plate. The limit of detection for this method was approximately 10 CFU/mL.

Peptides binding to Dacron: To determine how much peptide impregnates the graft, 1 cm² slices of collagen-sealed Dacron (AlbograftTM, Sorin Biomedica Cardio, S.p.A., Saluggi VC, Italy) were soaked at room temperature in peptide solutions, in quadruplicates, for 0.5 or 5 hrs (1 mL saline per graft, containing 50 µg/mL of each peptide). Following the incubation period the Dacron was removed and residual peptide (unbound fraction) was subjected to reversed phase-HPLC analysis as described above. Peptide identification was based on retention time and spectral analysis. The amount of unbound peptide was calculated by area integration of the UV absorbing peak (220 nm) and comparison with standard curves of known concentrations for each peptide (18).

RNAIII synthesis and bacterial growth: *S. aureus* cells containing the *rnaiii::blaZ* fusion construct (27) (30µl, 2x10⁷ cells) were grown for 2.5 hrs with 5µL peptides or control buffer. A sample (5µL) was removed, diluted in saline, and streaked on LB agar plates to determine CFU. The rest of the reaction mixture was used to determine RNAIII synthesis (beta-lactamase activity). This was done by adding a substrate of beta-lactamase (nitrocefin), and OD determined at 490nm/650nm (27).

Statistical analysis: MIC values are presented as the geometric mean of three separate experiments. Quantitative culture results from all groups were presented as mean ± standard

deviation and the statistical comparisons between groups were made using analysis of variance (ANOVA) on the log-transformed data. Significance was accepted when the P value was ≤ 0.05 .

RESULTS

Prevention of graft-associated infections

The peptides DD₁₃ and RIP (Table 1) were tested for efficacy in preventing staphylococcal graft-associated infections. Collagen-coated Dacron grafts were coated with 10, 20 or 50 mg/L of either RIP or DD₁₃ and were implanted in rats. Bacteria (MRSA or MRSE) were injected into the implants, implants removed after a week, and bacterial load determined. The study included a negative control group (untreated graft with no bacterial challenge) and a positive control group (untreated graft with bacterial challenge). The results are summarized in Figure 1. None of the animals included in the negative control group had anatomic or microbiological evidence of graft infection (no graft contamination). All rats included in the positive control groups that were implanted with untreated grafts and challenged with MRSA or MRSE (total of 30 rats) demonstrated evidence of graft infection, with quantitative culture results showing $4.4 \times 10^6 \pm 1.2 \times 10^6$ and $6.9 \times 10^6 \pm 1.8 \times 10^6$ CFU/ml graft, respectively.

Animals implanted with grafts presoaked in 10, 20 or 50 mg/L RIP solutions and challenged with MRSA, demonstrated reduced evidence of infection with $4.1 \times 10^4 \pm 7.1 \times 10^3$, $5.9 \times 10^3 \pm 1.7 \times 10^3$ and $8.4 \times 10^1 \pm 3.6 \times 10^1$ CFU/ml respectively, and those challenged with MRSE demonstrated reduced evidence of infection with $6.9 \times 10^3 \pm 1.9 \times 10^3$, $8.5 \times 10^2 \pm 2.0 \times 10^2$ and $3.9 \times 10^1 \pm 1.6 \times 10^1$ CFU/ml, respectively.

Animals implanted with grafts presoaked with DD₁₃ and challenged with MRSA, demonstrated reduced or no evidence of infection with $5.2 \times 10^2 \pm 1.6 \times 10^2$, $4.0 \times 10^1 \pm 1.7 \times 10^1$ CFU/ml and negative quantitative cultures, respectively for the same doses as RIP.

Similarly, animals challenged with MRSE, demonstrated reduced or no evidence of infection with $5.2 \times 10^2 \pm 1.6 \times 10^2$, $4.4 \times 10^1 \pm 1.3 \times 10^1$ CFU/ml and negative quantitative cultures, respectively.

In addition, treatment with these peptides was compared with the conventionally used antibiotic, Rifampin (60). These experimental groups received grafts pre-soaked with 5 mg/L rifampin alone, or rifampin and RIP or DD₁₃ at 10 mg/L. The group of rifampin-treated rats showed quantitative culture of $6.7 \times 10^3 \pm 9.1 \times 10^2$ CFU/mL MRSA and $8.8 \times 10^2 \pm 3.0 \times 10^2$ CFU/mL MRSE, but when soaked in combination with RIP or DD₁₃, animals showed negative quantitative cultures and no evidence of infection.

Of note is that all agents used did not show any signs of toxicity and none of the animals included in any group died or had clinical evidence of drug related adverse effects, such as local signs of perigraft inflammation, anorexia, vomiting, diarrhea, and behavioral alterations. Reduction in bacterial load was significant ($p < 0.05$) in all experimental groups when compared to positive control groups.

In vitro studies

Peptide binding to Dacron cuffs: To verify the relationships between the observed in vivo activity and the amount of peptide present on the Dacron grafts, the grafts were soaked in peptide solutions as described above prior to be grafted in rats. After removing the grafts, the solutions were subjected to HPLC analysis from which the amount of Dacron-bound peptide was deduced from calculated amount of residual unbound fraction. The results are summarized in Figure 3 for a peptide solution of 50 mg/L. RIP bound the least with a mean bound amount of $6.5 \pm 2.5 \mu\text{g}/\text{cm}^2$. DD₁₃ was found to bind more significantly than RIP with a

mean bound amount of $27 \pm 0.5 \mu\text{g}/\text{cm}^2$. The data indicates that longer soaking time periods enable uptake of larger amounts of each peptide. For instance, nearly 100% (i.e., 50 μg) of DD₁₃ was found to bind after 5 hours soaking (data not shown). While these experiments indicate that in the future, longer soaking time will result in higher peptide concentrations on the grafts, they also demonstrate that the higher protective efficacy of the bactericidal peptide as compared to RIP is not due to its relative concentration but rather to its specific activity (see below).

Bacterial growth and RNAIII synthesis: To better understand the molecular mechanisms involved in the observed activity, the peptides were investigated for their effect(s) in vitro on RNAIII synthesis (known to be inhibited by RIP) and for bacterial proliferation (known to be inhibited by DD₁₃). These experiments were performed by growing *S. aureus* cells containing an *rnaiii::blaZ* fusion construct in the presence of either one the peptides. Cultures were followed by determination of RNAIII synthesis by a colorimetric method using nitrocefin as a substrate while the peptides effect on bacterial viability was assessed by performing CFU counts using conventional microbiological methods. The results are summarized in Figure 4.

DD₁₃ displayed potent bactericidal activity whereas RIP was virtually inactive (Fig. 4, panel A). According to the broth-microdilution method, DD₁₃ exhibited a MIC at 2 mg/L for both staphylococcal strains (as compared to susceptibility to rifampin of MIC values of 0.5 mg/L for both of the organisms). RIP did not demonstrate any in vitro bactericidal activity against neither of the two strains, when tested up to 128 mg/L (data not shown).

As also shown in Fig. 4, RIP efficiently inhibited RNAIII synthesis while DD₁₃ appeared to be more efficient than RIP. However, closer inspection of the data revealed that at high peptide concentrations, most of the inhibitory activity observed was attributable to cell

death. Moreover, at low peptide concentrations, where no cell death occurred, DD₁₃ was unable to affect RNAPIII synthesis (Inset of Figure 4, panel B).

DISCUSSION

In order to prove efficacy in preventing bacterial adhesion and biofilm formation *in vivo*, a well characterized experimental Dacron graft rat model was used. For comparison purposes the antibiotic rifampin was chosen for its current utilization in clinical practice against *staphylococci* (60). Rifampin was very effective in our experimental model, as expected from previous literature (3, 24). However, like with RIP alone, rifampin did not eradicate bacterial infection. 100% inhibition was reached only when rifampin was combined with a peptide. The reason why RIP did not cause total inhibition when used alone could be due to the actual amount of RIP bound to the graft. It is estimated that soaking the graft in 50 mg/L RIP resulted in 6.5 ± 2.5 μ g RIP bound to the graft before implantation, which may not be enough to prevent adhesion of the 10 million cells that were injected. Perhaps if the grafts were coated with a higher concentration of RIP such as after longer soaking time, better prevention could have been reached with RIP and other peptides. Note however, that such a high level of a single dose of bacterial contamination is unlikely to occur in clinical settings, suggesting that the amounts of bound peptides as utilized in the present *in vivo* experiments could be sufficient to pre-coat grafts in clinical practice..

The present study also demonstrates that like RIP, the 13-residue dermaseptin derivative DD₁₃ is highly efficient in inhibiting staphylococcal infections whether used alone or in combination with the conventional antibiotic. In fact, DD₁₃ was significantly more efficient than RIP. According to our estimation, the amount of peptide present on the graft excludes the possibility that efficacy was proportional to some higher quantity of bound peptide. Thus, while DD₁₃ had about threefold higher binding than RIP, efficacy *in-vivo* was

at least tenfold higher at each one of the concentrations used. This suggests that the high efficacy of DD₁₃ in-vivo is not due to its relative concentration on the graft but rather to its specific activity.

In addition, the use of DD₁₃ might be preferable over RIP due to the peptide's ability to kill bacteria and simultaneously neutralize the threat that the bacteria might release endotoxins which can cause septic shock upon their introduction into the bloodstream. Antimicrobial peptides such the dermaseptin are known for their ability to bind endotoxins and neutralize them and thereby prevent septic shock.

In conclusion, I show in this disclosure an alternative approach to preventing device-associated infection by *S. aureus* and *S. epidermidis*. Since DD₁₃ is highly effective in preventing staphylococcal infections, our data suggests that DD₁₃ could be used to coat medical devices known to be associated with staphylococcal infections.

FOOTNOTES

Acknowledgments: This research was partly supported by the DA'AT consortium, a Magnet project administrated by the Office of the Chief Scientist at the Ministry of Industry, and partly by the Technion's President Research Fund.

Key Words: Antimicrobial peptides; Bacteria; Quorum sensing; RNAIII inhibiting peptide; Dacron; Biofilm.

Abbreviations: RIP: RNAIII inhibiting peptide; DD₁₃: a 13-mer dermaseptin derivative; MRSA: methicillin-resistant *Staphylococcus aureus*; MRSE: methicillin-resistant *S. epidermidis*; TRAP: target of RNAIII-activating protein; Fmoc: 9-fluorenylmethyloxycarbonyl; MBHA: 4-methylbenzhydramine. CFU: colony forming unit. CD: circular dichroism.

REFERENCES

1. Andreu, D., Rivas, L. 1998. Animal antimicrobial peptides: an overview. *Biopolymers*. 47: 415-33
2. Balaban, N., Collins, L.V., Cullor, J.S., Hume, E.B., Medina-Acosta, E., Vieira da Motta, O., O'Callaghan, R., Rossitto, P.V., Shirliff, M.E., Serafimda Silveira, L., Tarkowski, A., Torres, J.V. 2000. Prevention of diseases caused by *Staphylococcus aureus* using the peptide RIP. *Peptides*. 21: 1301-1311
3. Balaban, N., Giacometti, A., Cirioni, O., Gov, Y., Ghiselli, R., Mocchegiani, F., Viticchi, C., Del Prete, M.S., Saba, V., Scalise, G., Dell'Acqua, G. 2003. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant *Staphylococcus epidermidis*. *J Infect Dis*. 187: 625-30
4. Balaban, N., Goldkorn, T., Gov, Y., Hirshberg, M., Koyfman, N., Matthews, H.R., Nhan, R.T., Singh, B., Uziel, O. 2001. Regulation of *Staphylococcus aureus* pathogenesis via target of RNAIII-activating Protein (TRAP). *J Biol Chem*. 276: 2658-2667
5. Balaban, N., Goldkorn, T., Nhan, R.T., Dang, L.B., Scott, S., Ridgley, R.M., Rasooly, A., Wright, S.C., Larrick, J.W., Rasooly, R., Carlson, J.R. 1998. Autoinducer of virulence as a target for vaccine and therapy against *Staphylococcus aureus*. *Science*. 280: 438-440
6. Balaban, N., Gov, Y., Bitler, A., Boelaert, J.R. 2003. Prevention of *Staphylococcus aureus* biofilm on dialysis catheters and adherence to human cells. *Kidney Int*. 63: 340-345
7. Barie, P.S. 1998. Antibiotic-resistant gram-positive cocci: implications for surgical practice. *World J Surg*. 22: 118-126

8. **Blondelle, E.S. and Lohner, K. 2000. Combinatorial libraries: a tool to design antimicrobial and antifungal peptide analogues having lytic specificities for structure-activity relationship studies. *Biopolymers*. 55: 74-87**
9. **Boman, H.G. 1995. Peptide antibiotics and their role in innate immunity. *Annu. Rev. Immunol.* 13: 61-92**
10. **Brand, G.D., Leite, J.R., Silva, LP., Albuquerque, S., Prates, M.V., Azevedo, R.B., Carregaro, V., Da Silva, J.S., Sa, V.C., Brandao, R.A., Bloch, C. Jr. 2002. Dermaseptins from *Phyllomedusa oreades* and *Phyllomedusa distincta*. Anti-Trypanosoma cruzi activity without cytotoxicity to mammalian cells. *J Biol Chem*. 277: 49332-40**
11. **Carratala, J. 2002. The antibiotic-lock technique for therapy of 'highly needed' infected catheters. *Clin. Microbiol. Infect.* 8: 282-9**
12. **Chen, J., T. J. Falla., H. Liu., M. A. Hurst., C. A. Fujii., D. A. Mosca., J. R. Embree., D. J. Loury., P. A. Radcl., C. C. Chang., L. Gu., J. C. Fiddes. 2000. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. *Biopolymers*. 55: 88-98**
13. **Chicharro C, Granata C, Lozano R, Andreu D, Rivas L. 2001. N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide. *Antimicrob Agents Chemother*. 45: 2441-9**
14. **Costerton, J.W., Stewart, P.S., Greenberg, E.P. 1999. Bacterial biofilms: a common cause of persistent infections. *Science* 284: 1318-1322**
15. **Dagan, A., Efron, L., Gaidukov, L., Mor, A. and Ginsburg, H. 2002. In vitro antiplasmodium effects of dermaseptin S4 derivatives. *Antimicrob. Agents Chemother*. 46: 1059-66**
16. **Duclobier, H. and Wroblewski, H. 2001. Voltage-dependent pore formation and antimicrobial activity by alamethicin and analogues. *J. Membr. Biol.* 184: 1-12**

17. Edlund, C., Hedberg, M., Engstrom, A., Flock, J.I., Wade, D. 1998. Antianaerobic activity of a cecropin-melittin peptide. *Clin Microbiol Infect.* 4: 181-185
18. Feder, R., Dagan, A. and Mor, A. 2000. Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. *J. Biol. Chem.* 275: 4230-38
19. Feder, R., Nehushtai, R. and Mor, A. 2001. Affinity driven molecular transfer from erythrocyte membrane to target cells. *Peptides.* 22: 1683-90
20. Friedrich, C.L., Moyles, D., Beveridge, T.J. and Hancock, R.E. 2000. Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. *Antimicrob. Agents Chemother.* 44: 2086-92
21. Ganz, T. and Lehrer, R. 1998. Antimicrobial peptides of vertebrates. *Curr. Opin. Immunol.* 10: 41-44
22. Gazit, E., Boman, A., Boman, H.G. and Shai, Y. 1995. Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. *Biochemistry.* 34: 11479-88
23. Ge, Y., MacDonald, D.L., Holroyd, K.J., Thornsberry, C., Wexler, H., and Zasloff, M. 1999. In vitro antibacterial properties of pexiganan, an analog of magainin. *Antimicrob. Agents Chemother.* 43: 782-788
24. Giacometti, A., Cirioni, O., Gov, Y., Ghiselli, R., Del Prete, D.S., Mocchegiani, F., Saba, V., Orlando, F., Scalise, G., Balaban, N., Dell'Acqua, G. (2003) *Antimicrobial Agents and Chemotherapy*, In Press.
25. Ghosh, J.K., Shaool, D., Guillaud, P., Ciceron, L., Mazier, D., Kustanovich, I., Shai, Y. and Mor, A. 1997. Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic *Plasmodium falciparum* and the underlying molecular basis. *J. Biol. Chem.* 272: 31609-16

26. **Gottenbos, B, Grijpma, D.W., van der Mel, H.C., Feijen, J., Busscher, H.J.**
2001. Antimicrobial effects of positively charged surfaces on adhering Gram-positive and Gram-negative bacteria. *J Antimicrob Chemother.* 48: 7-13
27. **Gov, Y., Bitler, A., Dell'Acqua, G., Torres, JV., Balaban, N.** (2001)
Peptides. 22: 1609-20
28. **Hancock, R.E.** 1997. Peptide antibiotics. *The Lancet.* 349: 418-22
29. **Hancock, R.E. and Lehrer, R.** 1998. Cationic peptides: a new source of antibiotics. *Trends Biotechnol.* 16: 82-90
30. **Hariton-Gazal E, Feder R, Mor A, Graessmann A, Brack-Werner R, Jans D, Gilon C, Loyter A.** 2001. Targeting of nonkaryophilic cell-permeable peptides into the nuclei of intact cells by covalently attached nuclear localization signals. *Biochemistry.* 41: 9208-14
31. **Heller, W.T., Waring, A.J., Lehrer, R.I., Huang, H.W.** 1998. Multiple states of beta-sheet peptide protegrin in lipid bilayers. *Biochemistry.* 37: 17331-38
32. **Henke, P.K., Bergamini, T.M., Rose, S.M., Richardson, J.D.** 1998. Current options in prosthetic vascular graft infection. *Am Surg* 64: 39-45
33. **Huang, H.W.** 2000. Action of antimicrobial peptides: two-state model. *Biochemistry.* 39: 8347-52
34. **Huebner, J., Goldman, D.A.** 1999. Coagulase-negative staphylococci: role as pathogens. *Ann. Rev. Med.* 50: 233-236
35. **Kustanovich, I., Shalev, D.E., Mikhlin, M., Gaidukov, L., Mor, A.** 2002. Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. *J. Biol. Chem.* 277: 16941-51

36. **Ladokhin, A.S., Selsted, M.E. and White, S.H. 1997. Sizing membrane pores in lipid vesicles by leakage of co-encapsulated markers: pore formation by melittin. *Biophys. J.* 72: 1762-66**
37. **Levy, O. 2000. Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. *Blood.* 96: 2664-72**
38. **Linnola, R. 2001. Staphylococcus epidermidis and intraocular lenses. *Ophthalmology* 108: 1518-1519**
39. **Lowy, F.D. 1998. Staphylococcus aureus infections. *N. Engl. J. Med.* 339: 520-532**
40. **Ludtke, S.J., He, K., Wu, Y., Huang, H.W. 1994. Cooperative membrane insertion of magainin correlated with its cytolytic activity. *Biochim. Biophys. Acta.* 1190: 181-4**
41. **Mah, T.F., O'Toole, G.A. 2001. Mechanisms of biofilm resistance to antimicrobial agents. *Trends Microbiol.* 9: 34-39**
42. **Maloy, L.W. and Kari U.P. 1995. Structure-activity studies on magainins and other host defense peptides. *Biopolymers.* 37: 105-22**
43. **Marr, K.A. 2000. Staphylococcus aureus bacteremia in patients undergoing hemodialysis. *Seminars in Dialysis.* 13: 23-29**
44. **Merrifield RB, Merrifield EL, Juvvadi P, Andreu D, Boman HG. 1994. Design and synthesis of antimicrobial peptides. *Ciba Found Symp.* 186: 5-20**
45. **Miller, M.B., Bassler, B.L. 2001. Quorum sensing in bacteria. *Annu Rev Microbiol.* 55: 165-199**
46. **Moll, G.N., Brul, S., Konings, W.N., Driessen, A.J. 2000. Comparison of the membrane interaction and permeabilization by the designed peptide Ac-MB21-NH₂ and truncated dermaseptin S3. *Biochemistry.* 39: 11907-12**

47. Mor, A. 2001. Antimicrobial peptides. The Kirk-Othmer Encyclopedia of Chemical Technology. John Wiley & Sons. <http://www3.interscience.wiley.com:8095/articles/peptwise.a01/frame.html>
48. Mor, A., Amiche, M. and Nicolas, P. 1994. Structure, synthesis, and activity of dermaseptin b, a novel vertebrate defensive peptide from frog skin: relationship with adenoregulin. *Biochemistry*. 33: 6642-50
49. Mor, A., Hani, K., Nicolas, P. 1994. The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. *J. Biol. Chem.* 269: 31635-40
50. Mor, A., Nguyen, V.H., Delfour, A., Migliore, S.D. and Nicolas, P. 1991. Isolation, amino acid sequence, and synthesis of dermaseptin, a novel antimicrobial peptide of amphibian skin. *Biochemistry*. 30: 8824-30.
51. Mor, A. and Nicolas, P. 1994. Isolation and structure of novel defensive peptides from frog skin. *Eur. J. Biochem.* 219: 145-54
52. Mor, A. and Nicolas, P. 1994. The NH₂-terminal alpha-helical domain 1-18 of dermaseptin is responsible for antimicrobial activity. *J. Biol. Chem.* 269: 1934-39
53. Navon-Venezia, S., Feder, R., Gaidukov, L., Carmeli, Y., and Mor, A. 2002. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. *Antimicrob. Agents Chemother.* 46: 689-694
54. Nicolas, P. and Mor, A. 1995. Peptides as weapons against microorganisms in the chemical defense system of vertebrates. *Annu. Rev. Immunol.* 49: 277-304
55. Oren, Z. and Shai, Y. 2000. Cyclization of a cytolytic amphipathic alpha-helical peptide and its diastereomer: effect on structure, interaction with model membranes, and biological function. *Biochemistry*. 39: 6103-6114

56. Oren, Z. and Shai, Y. 1998. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. *Biopolymers*. 47: 451-63
57. Patrzykat A, Friedrich CL, Zhang L, Mendoza V, Hancock RE. 2002. Sublethal concentrations of pleurocidin-derived antimicrobial peptides . inhibit macromolecular synthesis in *Escherichia coli*. *Antimicrob Agents Chemother*. 46: 605-14
58. Piers KL, Brown MH, Hancock RE. 1994. Improvement of outer membrane-permeabilizing and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification. *Antimicrob Agents Chemother*. 38: 2311-6
59. Pouny, Y., Rapaport, D., Mor, A., Nicolas, P. Shai, Y. 1992. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. *J. Biol. Chem*. 31: 12416-23
60. Sardelle, F., P.Y. Ao, D.A. Taylor, J.P. Fletcher. 1996. Prophylaxis against *Staphylococcus epidermidis* vascular graft infection with rifampicin-soaked, gelatin-sealed Dacron. *Cardiovasc. Surg*. 4: 389-392
61. Schierholz, J.M., Beuth, J. 2001. Implant infections: a haven for opportunistic bacteria. *J. Hosp. Infect*. 49: 87-93
62. Shai, Y. 2002. Mode of action of membrane active antimicrobial peptides. *Biopolymers*. 66: 236-48
63. Shai, Y. 1999. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. *Biochim. Biophys. Acta*. 1462: 55-70
64. Shin SY, Kang JH, Lee MK, Kim SY, Kim Y, Hahm KS. 1998. Cecropin A - magainin 2 hybrid peptides having potent antimicrobial activity with low hemolytic effect. *Biochem Mol Biol Int*. 44: 1119-26

65. Sokolov, Y., Mirzabekov, T., Martin, D.W., Lehrer, R.I. and Kagan, B.L. 1999. Membrane channel formation by antimicrobial protegrins. *Biochim. Biophys. Acta.* 1420: 23-9
66. Stewart, P.S. and Costerton, J.W. 2001. Antibiotic resistance of bacteria in biofilms. *Lancet.* 358: 135-138
67. Strahilevitz, J., Mor, A., Nicolas, P. and Shai, Y. 1994. Spectrum of antimicrobial activity and assembly of dermaseptin-b and its precursor form in phospholipid membranes. *J. Biol. Chem.* 33: 10951-60
68. Tiller, J.C., Liao, C.J., Lewis, K., Klubanov, A.M. 2001. Designing surfaces that kill bacteria on contact. *Proc Natl Acad Sci USA.* 98: 5981-5
69. Tossi, A., Sandri, L., Giangaspero, A. 2000. Amphipathic, alpha-helical antimicrobial peptides. *Biopolymers.* 55: 4-30
70. Vieira-da-Motta, O., Damasceno, Ribeiro P., Dias da Silva, W., Medina-Acosta, E. 2001. RNAIII inhibiting peptide (RIP), a global inhibitor of *Staphylococcus aureus* pathogenesis: structure and function analysis. *Peptides.* 22: 1621-1627
71. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. *Nature.* 415: 389-95

FIGURE LEGENDS

Figure 1. Peptides effect on graft associated infections in rats. Dacron grafts were pre-soaked in saline (control), RIP or DD₁₃, at the designated concentrations and implanted in rats. Grafts were then inoculated with methicillin-resistant *S. aureus* (MRSA) or a clinical isolate of methicillin-resistant *S. epidermidis* (MRSE). Grafts were removed after a week and assessed for bacterial load. Plots show typical counts of viable CFUs for MRSA (triangles) or MRSE (circles). Statistical data is detailed in Results section.

Figure 2. Prevention of graft associated infections in rats based on combined therapy. Grafts pre-soaked in saline (control), rifampin alone (5 mg/L) or rifampin combined with either RIP or DD₁₃ (10 mg/L) were implanted in rats and inoculated with MRSA or MRSE. Grafts were removed after a week and assessed for bacterial load. Plots show the resulting counts of viable CFU. Statistical data is detailed in Results section. A star indicates negative quantitative cultures.

Figure 3. Peptides binding to Dacron: Collagen-sealed Dacron grafts were soaked in peptide solutions (50 mg/L). Bound peptide was estimated from unbound fraction that was subjected to analytical reversed-phase HPLC. Peptide identification was based on retention time and spectral analysis. Unbound peptide was determined after area integration of the UV absorbing peak (220 nm) and comparison with standard curves of known concentrations (18). Error bars indicate standard deviations of the mean determined from four independent experiments.

Figure 4. In-vitro effects of peptides on bacterial growth and RNAPIII synthesis. *S. aureus* cells containing *rnapiii::blaZ* fusion construct ($\sim 2 \times 10^7$ cells) were grown with peptides or control buffer then divided to two portions. One portion was diluted in saline and streaked on LB agar plates to determine CFU (panel A). The other portion was used to determine RNAPIII synthesis (panel B) by adding the beta-lactamase substrate nitrocefin, and measuring

OD at 490nm/650nm (27). Error bars indicate standard deviations from the mean as determined from two independent experiments performed in triplicates. Inset: Same as panel B focussing on low peptide concentrations. Symbols in panel B are as in panel A.

Claims:

1. The use of a dermaseptin derivative essentially as described herein and its functional analogs or equivalents for preventing graft associated infections of antibiotic-resistant *staphylococci*.
2. The use of a dermaseptin derivative essentially as described herein and its functional analogs or equivalents for treating bacterial infections.
3. The use of a dermaseptin derivative essentially as described herein and its functional analogs or equivalents for treating *staphylococci* infections.

Table 1

Primary structures and designations of the peptides investigated.

Peptide	Amino acid sequence	Designation
RIP	YSPWTNF _{CONH2}	RIP
K ₄ -S4 (1-13) _a	ALWKTLLKKVLKA _{CONH2}	DD ₁₃

A DERMASEPTIN DERIVATIVE (DD₁₃) PREVENTS GRAFT ASSOCIATED INFECTIONS OF ANTIBIOTIC-RESISTANT *STAPHYLOCOCCI*

Inventor: Amram Mor

ABSTRACT

Staphylococcal bacteria are a prevalent cause of infections associated with foreign bodies and indwelling medical devices. Bacteria are capable of escaping antibiotic treatment through encapsulation into biofilms. RIP is a heptapeptide that inhibits staphylococcal biofilm formation by obstructing quorum sensing mechanisms. K₄-S4(1-13)_a is a 13-residue dermaseptin derivative (DD₁₃) believed to kill bacteria via membrane disruption. I tested each of these peptides for their ability to inhibit bacterial proliferation and suppress quorum sensing in vitro, and for their efficacy in preventing staphylococcal infection in a rat graft infection model using *S. aureus* (MRSA) or *S. epidermidis* (MRSE). In vitro, proliferation assays demonstrated that RIP had no inhibitory effect while, at least at non-cytolytic doses, DD₁₃ was unable of inhibiting RNAPIII synthesis, a regulatory RNA molecule important for staphylococcal pathogenesis. In vivo, both peptides reduced graft associated bacterial load in a dose dependant manner but the bactericidal peptide was more potent in totally preventing *Staphylococcal* infections at the lowest dose. In addition, both peptides acted synergistically with antibiotics. The data indicates that DD₁₃ may be useful for coating medical devices to prevent drug-resistant staphylococcal infections.

Figure 1.




Figure 2




Figure 3





Figure 4



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.